Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 157 results for fibrosis

  1. Osteoporosis: assessing the risk of fragility fracture (CG146)

    This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.

    Clinical guideline
    Last updated
    7 February 2017
    View recommendations

    Sections for CG146

  2. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)

    NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .

    Medtech innovation briefing
    Published
    10 July 2020

  3. Sipavibart for preventing COVID-19 [ID6282]

    In development [GID-TA11352] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  4. Data collection agreement

    This agreement relates to treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor (Kaftrio®) in combination with...

  5. Airway clearance techniques:- How effective are daily airway clearance techniques in maintaining lung function in infants and children with cystic fibrosis?

    techniques in maintaining lung function in infants and children with cystic fibrosis? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    6 November 2018

  6. Psychological assessment:- What is the most effective measure of psychological functioning to use as a test for thresholds of concern in people with cystic fibrosis?

    functioning to use as a test for thresholds of concern in people with cystic fibrosis? Any explanatory notes(if applicable) Why this is...

    Research recommendation
    Published
    18 October 2018

  7. Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

    Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.

    Interventional procedures guidance
    Published
    23 July 2008
    View recommendations

    Sections for IPG268

  8. Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)

    Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    26 October 2016
    View recommendations

    Sections for TA413

  9. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

    Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.

    Technology appraisal guidance
    Last updated
    1 November 2013
    View recommendations

    Sections for TA75

  10. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

    Technology appraisal guidance
    Published
    22 July 2009
    View recommendations

    Sections for TA173

  11. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

    Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.

    Technology appraisal guidance
    Published
    25 November 2015
    View recommendations

    Sections for TA365

  12. Living-donor lung transplantation for end-stage lung disease (IPG170)

    Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.

    Interventional procedures guidance
    Published
    24 May 2006
    View recommendations

    Sections for IPG170

  13. Further research is recommended on:• the impact of magnetic resonance elastography (MRE) test results on decisions about care, such as the decision to do a liver biopsy, or on adherence to lifestyle interventions (see section 3.5 )• the test accuracy of MRE to assess the level of fibrosis or presence of cirrhosis compared with biopsy at thresholds specified by the company, or the prognostic ability of MRE to predict clinical outcomes (see section 3.20 ).

    interventions (see section 3.5 )• the test accuracy of MRE to assess the level of fibrosis or presence of cirrhosis compared with biopsy...

    Research recommendation
    Published
    3 February 2023

  14. Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant (IPG695)

    Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of lungs for transplant. This involves using a machine to deliver an oxygenated solution to a donor lung and keep it at normal body temperature until it can be transplanted.

    Interventional procedures guidance
    Published
    26 May 2021
    View recommendations

    Sections for IPG695

  15. Taking a proportionate approach to technology appraisals

    Find out more about NICE's new proportionate approach to technology appraisals